tadalafil has been researched along with Sclerosis, Systemic in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Baniotopoulos, P; Dimitroulas, T; Hatzichristodoulou, G; Minopoulou, I; Pyrgidis, N; Sokolakis, I; Tishukov, M | 2 |
| Fernández-Codina, A; Kazem, M; Pope, JE | 1 |
| Blair, C; Coghlan, JG; Kuwana, M; Langley, J; Takahashi, T | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Nikpour, M; Proudman, SM; Stevens, WM; Thakkar, V | 1 |
| Chin, K; Corona-Villalobos, CP; Damico, R; Gashouta, MA; Girgis, RE; Hassoun, PM; Housten, T; Hulme, OL; Khair, R; Kolb, TM; Lechtzin, N; Mathai, SC; Minai, OA; Pisanello, C; Pullins, EH; Sato, T; Tedford, RJ; Torres, F; Zamanian, RT; Zimmerman, SL | 1 |
| Khanna, D; McLaughlin, V | 1 |
| Cheong, FY; Farber, HW; Gower, AC | 1 |
| Barberà, JA; Blair, C; Coghlan, JG; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Harris, JHN; Hoeper, MM; Kuwana, M; Langley, J; McLaughlin, VV; Miller, KL; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiéry, JL | 1 |
| Hsu, VM; Impens, AJ; McCloskey, DA; Phillips, K; Rothman, JA; Schiopu, E; Seibold, JR; Wilson, JE | 1 |
| Agarwal, V; Choudhary, SK; Jha, LK; Kumar, S; Misra, R; Shenoy, PD; Singh, U | 1 |
| Nagle, DJ; Patel, RM | 1 |
| Aversa, A; Bruzziches, R; Letizia, C; Menghi, G; Merla, A; Proietti, M; Rossi, C; Salsano, F; Spera, G | 1 |
3 review(s) available for tadalafil and Sclerosis, Systemic
| Article | Year |
|---|---|
Treatment of Sexual Dysfunction in Women with Systemic Autoimmune Rheumatic Disorders: A Systematic Review.
Topics: Androgens; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Humans; Lubricants; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sexual Dysfunction, Physiological; Tadalafil; Testosterone | 2022 |
Treatment of Sexual Dysfunction in Women with Systemic Autoimmune Rheumatic Disorders: A Systematic Review.
Topics: Androgens; Female; Humans; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sexual Dysfunction, Physiological; Tadalafil | 2022 |
Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Tadalafil; Treatment Outcome | 2015 |
5 trial(s) available for tadalafil and Sclerosis, Systemic
| Article | Year |
|---|---|
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Topics: Adult; Comorbidity; Connective Tissue Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Phenylpropionates; Proportional Hazards Models; Pulmonary Arterial Hypertension; Pyridazines; Risk Assessment; Scleroderma, Systemic; Tadalafil; Treatment Outcome; Vasodilator Agents | 2020 |
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Scleroderma, Systemic; Tadalafil | 2017 |
Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
Topics: Adult; Carbolines; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Prospective Studies; Raynaud Disease; Scleroderma, Systemic; Tadalafil; Treatment Outcome | 2009 |
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Topics: Adult; Carbolines; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Tadalafil; Treatment Outcome; Vasodilator Agents; Young Adult | 2010 |
Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
Topics: Adult; Carbolines; Disease Progression; Endothelin-1; Erectile Dysfunction; Health Surveys; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Scleroderma, Systemic; Tadalafil | 2007 |
6 other study(ies) available for tadalafil and Sclerosis, Systemic
| Article | Year |
|---|---|
Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Topics: Administration, Cutaneous; Adult; Aged; Female; Fingers; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Raynaud Disease; Scleroderma, Systemic; Skin Cream; Tadalafil; Ulcer | 2020 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Topics: Drug Therapy, Combination; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptide, Brain; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pyridazines; Scleroderma, Systemic; Stroke Volume; Tadalafil; Ultrasonography; Vascular Resistance | 2015 |
Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!
Topics: Female; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Scleroderma, Systemic; Tadalafil | 2015 |
Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil.
Topics: Aged; Down-Regulation; Extracellular Matrix; Female; Golgi Apparatus; Humans; Hypertension, Pulmonary; Immunity, Innate; Interleukin-12; Male; Microarray Analysis; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Potassium Channels, Voltage-Gated; Scleroderma, Systemic; Signal Transduction; Tadalafil; Transcriptome; Treatment Outcome; Up-Regulation; Walk Test | 2017 |
Nonoperative management of scleroderma of the hand with tadalafil and subatmospheric pressure wound therapy: case report.
Topics: Adult; Carbolines; Combined Modality Therapy; Hand; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Negative-Pressure Wound Therapy; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Tadalafil; Wound Healing | 2012 |